← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV22행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyPhase 2
Azacytidine (Azacytidine)
M.D. Anderson Cancer Center·Hodgkin's Lymphoma
ORR 48%
Overview
Program
Azacytidine
Overview
Company
M.D. Anderson Cancer Center
Overview
Modality
ANTIBODY
Overview
Target
Hodgkin's Lymphoma
Overview
Indication
Hodgkin's Lymphoma
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
MoA
Mechanism
CAR T cells sustained high levels of interferon-γ production, which induced immunogenic cell death in tumor cells and activated conventional dendritic cell
MoA
Biomarker
biomarker, we constructed PPI networks and applied three ML methods: least absolute shrinkage and selection o
PK/PD
Species
Mouse, Rat
PK/PD
Animal (cat.)
Mouse, Rat
PK/PD
Experiment
PD
Toxicology
Species
Mouse, Rat
Toxicology
Animal (cat.)
Mouse, Rat
Toxicology
Major finding
Dnmt1 associated Gja1 promoter methylation changes are implicated in Cx43 remodeling during acute myocardial ischemia/reperfusion injury.. DNA methylation has traditionally been regarded as a stable epigenetic modification. However, emerging evidence indicates that oxidative and genotoxic stress can induce locus-specific methylation changes that modulate transcriptional responses. The contribution…
Clinical
Primary efficacy
ORR 48%
Clinical
ORR
48%
Clinical
OS
62
Clinical
Result source
ClinicalTrials.gov NCT00660400
Clinical
Data Tier / Score
A · 53
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 13일 (1일 전)